Terms: = Liver cancer AND SETD2, ENSG00000181555, 29072
15 results:
1. Reconstruction of the regulatory hypermethylation network controlling hepatocellular carcinoma development during hepatitis C viral infection.
Antropova EA; Khlebodarova TM; Demenkov PS; Volianskaia AR; Venzel AS; Ivanisenko NV; Gavrilenko AD; Ivanisenko TV; Adamovskaya AV; Revva PM; Kolchanov NA; Lavrik IN; Ivanisenko VA
J Integr Bioinform; 2023 Sep; 20(3):. PubMed ID: 37978846
[TBL] [Abstract] [Full Text] [Related]
2. Alternative promoters in CpG depleted regions are prevalently associated with epigenetic misregulation of liver cancer transcriptomes.
Nepal C; Andersen JB
Nat Commun; 2023 May; 14(1):2712. PubMed ID: 37169774
[TBL] [Abstract] [Full Text] [Related]
3. Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring setd2 and LRP1B mutations.
Reiter FP; Rau M; Kunzmann V; Kickuth R; Klein I; Neumann O; Stenzinger A; Schirmacher P; Geier A
Z Gastroenterol; 2023 Jan; 61(1):71-75. PubMed ID: 36379463
[TBL] [Abstract] [Full Text] [Related]
4. Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib.
Salani F; Latarani M; Casadei-Gardini A; Gangadharannambiar P; Fornaro L; Vivaldi C; Pecora I; Massa V; Marisi G; Canale M; Ulivi P; Scartozzi M; Eccleston M; Masi G; Crea F
Epigenomics; 2022 May; 14(9):507-517. PubMed ID: 35473355
[TBL] [Abstract] [Full Text] [Related]
5. Circular RNA circ SET domain containing 2 (circsetd2) inhibits hepatocellular carcinoma cell proliferation and invasion
Sun K; Zhang L; Chen P; Qi D; Liu H; Bao H; Wang X; Li T
Bioengineered; 2022 Mar; 13(3):7293-7302. PubMed ID: 35260047
[TBL] [Abstract] [Full Text] [Related]
6. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
Grande E; Rodriguez-Antona C; López C; Alonso-Gordoa T; Benavent M; Capdevila J; Teulé A; Custodio A; Sevilla I; Hernando J; Gajate P; Molina-Cerrillo J; Díez JJ; Santos M; Lanillos J; García-Carbonero R
Oncologist; 2021 Nov; 26(11):941-949. PubMed ID: 34190375
[TBL] [Abstract] [Full Text] [Related]
7. Deficiency of Histone Methyltransferase SET Domain-Containing 2 in liver Leads to Abnormal Lipid Metabolism and HCC.
Li XJ; Li QL; Ju LG; Zhao C; Zhao LS; Du JW; Wang Y; Zheng L; Song BL; Li LY; Li L; Wu M
Hepatology; 2021 May; 73(5):1797-1815. PubMed ID: 33058300
[TBL] [Abstract] [Full Text] [Related]
8. setd2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
[TBL] [Abstract] [Full Text] [Related]
9. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
10. Genomic structures of dysplastic nodule and concurrent hepatocellular carcinoma.
Lee M; Kim K; Kim SY; Jung SH; Yoon J; Kim MS; Park HC; Jung ES; Chung YJ; Lee SH
Hum Pathol; 2018 Nov; 81():37-46. PubMed ID: 29949741
[TBL] [Abstract] [Full Text] [Related]
11. Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors.
Yabe M; Miranda RN; Medeiros LJ
Hum Pathol; 2018 Apr; 74():5-16. PubMed ID: 29337025
[TBL] [Abstract] [Full Text] [Related]
12. The Genetic Basis of Hepatosplenic T-cell Lymphoma.
McKinney M; Moffitt AB; Gaulard P; Travert M; De Leval L; Nicolae A; Raffeld M; Jaffe ES; Pittaluga S; Xi L; Heavican T; Iqbal J; Belhadj K; Delfau-Larue MH; Fataccioli V; Czader MB; Lossos IS; Chapman-Fredricks JR; Richards KL; Fedoriw Y; Ondrejka SL; Hsi ED; Low L; Weisenburger D; Chan WC; Mehta-Shah N; Horwitz S; Bernal-Mizrachi L; Flowers CR; Beaven AW; Parihar M; Baseggio L; Parrens M; Moreau A; Sujobert P; Pilichowska M; Evens AM; Chadburn A; Au-Yeung RK; Srivastava G; Choi WW; Goodlad JR; Aurer I; Basic-Kinda S; Gascoyne RD; Davis NS; Li G; Zhang J; Rajagopalan D; Reddy A; Love C; Levy S; Zhuang Y; Datta J; Dunson DB; Davé SS
Cancer Discov; 2017 Apr; 7(4):369-379. PubMed ID: 28122867
[TBL] [Abstract] [Full Text] [Related]
13. Colorectal cancer Genetic Heterogeneity Delineated by Multi-Region Sequencing.
Lu YW; Zhang HF; Liang R; Xie ZR; Luo HY; Zeng YJ; Xu Y; Wang LM; Kong XY; Wang KH
PLoS One; 2016; 11(3):e0152673. PubMed ID: 27023146
[TBL] [Abstract] [Full Text] [Related]
14. setd2 histone modifier loss in aggressive GI stromal tumours.
Huang KK; McPherson JR; Tay ST; Das K; Tan IB; Ng CC; Chia NY; Zhang SL; Myint SS; Hu L; Rajasegaran V; Huang D; Loh JL; Gan A; Sairi AN; Sam XX; Dominguez LT; Lee M; Soo KC; Ooi LL; Ong HS; Chung A; Chow PK; Wong WK; Selvarajan S; Ong CK; Lim KH; Nandi T; Rozen S; Teh BT; Quek R; Tan P
Gut; 2016 Dec; 65(12):1960-1972. PubMed ID: 26338826
[TBL] [Abstract] [Full Text] [Related]
15. LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of setd2.
Li H; An J; Wu M; Zheng Q; Gui X; Li T; Pu H; Lu D
Oncotarget; 2015 Sep; 6(29):27847-64. PubMed ID: 26172293
[TBL] [Abstract] [Full Text] [Related]
